Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images.

Authors:
Sager S; Kabasakal L; Ocak M; Maecke H; Uslu L and 5 more

Journal:
Nucl Med Commun

Publication Year: 2013

DOI:
10.1097/MNM.0000000000000006

PMCID:
PMC3815136

PMID:
24121313

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Nucl Med Commun

Abbreviation: Nucl Med Commun

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nuclear Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Safety, biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 99m Tc-maraciclatide in …
Gibbons T; Perkins A; Barnett J. (2024) - Transparency Score: 3/6
18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immuno…
Feng Y; Wang P; Chen Y and 1 more (2023) - Transparency Score: 3/6
BNMS UK PET standards.
Cook GJR; Dickson J; Chicklore S and 6 more (2023) - Transparency Score: 2/6
Clinical impact of molecular breast imaging as adjunct diagnostic modality in evaluation of indeter…
van Loevezijn AA; Corion CLS; Zeillemaker AM and 7 more (2023) - Transparency Score: 2/6
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D …
Uijen MJM; Privé BM; van Herpen CML and 7 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest There are no conflicts of interest."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025